Trial Profile
A Phase I Study of Topotecan by Intracerebral Clysis for the Treatment of Recurrent Primary Malignant Brain Tumors
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Jan 2017
Price :
$35
*
At a glance
- Drugs Topotecan (Primary)
- Indications Brain cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Feb 2013 Planned end date changed from 1 Mar 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 14 Feb 2013 Planned end date changed from 1 Mar 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
- 14 Feb 2013 Planned end date changed from 1 Mar 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.